Insight into the beneficial immunomodulatory mechanism of the sevoflurane metabolite hexafluoro-2-propanol in a rat model of endotoxaemia

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 468-479

  Urner, M ^a,b   Schlapfer M ^a,b   Herrmann, I K ^a   Hasler, M ^a   Schimmer, R R ^b   Booy, C ^a,b   Roth Z'graggen, B ^b   Rehrauer, H ^b   Aigner, F ^b   Minshall, R D ^d   Stark, W J ^c   Beck Schimmer, B ^a,b,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anaesthesia; Fluorinated carbon groups; Inflammation; Interleukin; Sepsis

Indexed keywords

HEXAFLUORO 2 PROPANOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; SEVOFLURANE; TOLL LIKE RECEPTOR 4; AUTACOID; CYTOKINE; ETHER DERIVATIVE; IMMUNOLOGICAL ADJUVANT; PROPANOL;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL DAMAGE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENDOTOXEMIA; GENE EXPRESSION; HEMODYNAMICS; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE INJURY; TUMOR INVASION; ANIMAL; BLOOD; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENETICS; KIDNEY; LIVER; METABOLISM; NEUTROPHIL; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHOCK, SEPTIC; STATISTICAL MODEL; WISTAR RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTOXEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; LINEAR MODELS; LIPOPOLYSACCHARIDES; LIVER; MALE; METHYL ETHERS; NEUTROPHILS; PROPANOLS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHOCK, SEPTIC;

EID: 84939268790     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12648     Document Type: Article

References (41)

1. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754-61.
2. Gaieski DF, Mikkelsen ME, Band RA et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045-53.
3. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
4. Landoni G, Fochi O, Tritapepe L et al. Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009; 75:269-73.
5. Beck-Schimmer B, Breitenstein S, Urech S et al. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 2008; 248:909-18.
6. Ferrero ME, Marni A, Gaja G, Salari PC, Tiengo M. Conditioning of immune response by anesthetics. Ann NY Acad Sci 1992; 650:331-6.
7. Kharasch ED, Coopersmith CM. Sleeping to survive? The impact of volatile anesthetics on mortality in sepsis. Anesthesiology 2013; 119:755-6.
8. De Conno E, Steurer MP, Wittlinger M et al. Anesthetic-induced improvement of the inflammatory response to one-lung ventilation. Anesthesiology 2009; 110:1316-26.
9. Julier K, da Silva R, Garcia C et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315-27.
10. Herrmann IK, Castellon M, Schwartz DE et al. Volatile anesthetics improve survival after cecal ligation and puncture. Anesthesiology 2013; 119:901-6.
11. Lee HT, Emala CW, Joo JD, Kim M. Isoflurane improves survival and protects against renal and hepatic injury in murine septic peritonitis. Shock 2007; 27:373-9.
12. Lucchinetti E, Schaub MC, Zaugg M. Emulsified intravenous versus evaporated inhaled isoflurane for heart protection: old wine in a new bottle or true innovation? Anesth Analg 2008; 106:1346-9.
13. Urner M, Limbach LK, Herrmann IK et al. Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol 2011; 45:617-24.
14. Herrmann IK, Castellon M, Schwartz DE et al. Intravenous application of a primary sevoflurane metabolite improves outcome in murine septic peritonitis: first results. PLOS ONE 2013; 8:e72057.
15. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009; 119:2868-78.
16. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000; 12:20-6.
17. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7.
18. Voigtsberger S, Lachmann RA, Leutert AC et al. Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury. Anesthesiology 2009; 111:1238-48.
19. Urner M, Limbach LK, Herrmann IK et al. Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol 2011; 45:617-24.
20. Kharasch ED, Karol MD, Lanni C, Sawchuk R. Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. Anesthesiology 1995; 82:1369-78.
21. Bozza FA, Salluh JI, Japiassu AM et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11:R49.
22. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-62.
23. Vermont CL, Hazelzet JA, de Kleijn ED, van den Dobbelsteen GP, de Groot R. CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care 2006; 10:R33.
24. Hewett JA, Schultze AE, VanCise S, Roth RA. Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest 1992; 66:347-61.
25. Guidet B, Aegerter P, Gauzit R Meshaka P, Dreyfuss D, CUB-Réa Study Group. Incidence and impact of organ dysfunctions associated with sepsis. Chest 2005; 127:942-51.
26. Dear JW, Yasuda H, Hu X et al. Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int 2006; 69:832-6.
27. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-87.
28. O'Seaghdha CM, Hwang SJ, Larson MG, Meigs JB, Vasan RS, Fox CS. Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol 2013; 24:1880-8.
29. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257:7847-51.
30. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res 1988; 48:1-8.
31. Voigtsberger S, Lachmann RA, Leutert AC et al. Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury. Anesthesiology 2009; 111:1238-48.
32. Hotchkiss RS, Tinsley KW, Swanson PE et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-63.
33. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-22.
34. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 1999; 5:298-302.
35. Hotchkiss RS, Chang KC, Swanson PE et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1:496-501.
36. Zhong C, Zhou Y, Liu H. Nuclear factor kappaB and anesthetic preconditioning during myocardial ischemia-reperfusion. Anesthesiology 2004; 100:540-6.
37. Loop T, Scheiermann P, Doviakue D et al. Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology 2004; 101:710-21.
38. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4:854-65.
39. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25:1095-100.
40. Laterre PF, Levy H, Clermont G et al. Hospital mortality and resource use in subgroups of the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit Care Med 2004; 32:2207-18.
41. Kharasch ED, Coopersmith CM. Sleeping to survive?: The impact of volatile anesthetics on mortality in sepsis. Anesthesiology 2013; 119:755-6.